Nachrichten zur AstraZeneca PLC Aktie

3 High-Yield Dividend Stocks to Buy in 2025

High-yield dividend stocks may not appeal to some investors. However, if youre among those investors looking for income, stocks that…

GOLDMAN SACHS stuft ASTRAZENECA auf Buy

NEW YORK (dpa-AFX Analyser) - Die US-Investmentbank Goldman Sachs hat die Einstufung für Astrazeneca auf "Buy" mit einem Kursziel von…

AZN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that AstraZeneca PLC Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

NEW YORK, Jan. 12, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally…

AZN INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that AstraZeneca PLC Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

SAN DIEGO, Jan. 11, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP…

Cancer Immunotherapy Global Market Overview 2023-2030, Competitive Analysis of Amgen, AstraZeneca,Bayer, BMS, Eli Lilly, F. Hoffmann-La Roche, GSK, Immunocore, J&J, Merck, Novartis, Pfizer

The global cancer immunotherapy market is primarily driven by the rising prevalence of cancer worldwide, leading to a growing demand…

ROSEN, THE FIRST FILING FIRM, Encourages AstraZeneca PLC Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – AZN

NEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm,…

3 Cheap Growth Stocks to Buy in 2025

As we enter 2025, many growth stocks are trading at high valuations and could be running out of room to…

ASTRAZENECA SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against AstraZeneca PLC - AZN

NEW ORLEANS, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former…

J&J says its lung cancer drug combination keeps people alive longer

Johnson & Johnson said its lung cancer regimen – Rybrevant plus Lazcluze – keeps people alive for at least a…

J&J lung cancer treatment extends lives versus AstraZeneca drug

Johnson & Johnson (NYSE:JNJ) has said its chemotherapy-free combination extended lung cancer patients’ lives compared to AstraZeneca PLC (LSE:AZN)’s...…

AstraZeneca: Uncertainty Ahead, Neutral Rating Confirmed.

…

Better Buy: Novo Nordisk vs. AstraZeneca

Novo Nordisk (NYSE: NVO) and AstraZeneca (NASDAQ: AZN) are among the largest companies in the pharmaceutical industry. Both have generally…

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages AstraZeneca PLC Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – AZN

NEW YORK, Jan. 03, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm,…

The Zacks Analyst Blog Eli Lilly, J&J, AbbVie, AstraZeneca and Pfizer

Eli Lilly, J&J, AbbVie, AstraZeneca and Pfizer are included in this Analyst Blog.…

Total Voting Rights

2 January 2025 Transparency Directive Voting rights and capital The following notification is made in accordance with the UK Financial Conduct Authoritys Disclosure…

5 Large Drug Stocks to Keep An Eye On in the New Year

R&D innovation is likely to remain a major focus area in 2025. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY),…

MNPR Stock Skyrockets 384% in 3 Months After Deal With AZN

Monopar stock skyrockets 384% in three months following a licensing deal with AstraZeneca for a late-stage Wilson Disease candidate.…

Hutchison (China) builds cash pile with joint venture stake disposal

AIM-quoted cancer treatments developer Hutchmed (China) Ltd (LON: HCM) is selling non-core 45% interest in Shanghai Hutchison Pharmaceuticals to GP…

AstraZeneca (AZN) Reels from China Investigation and Investor Suit – Hagens Berman

SAN FRANCISCO, Jan. 01, 2025 (GLOBE NEWSWIRE) -- AstraZeneca, the Anglo-Swedish pharmaceutical giant, has seen its stock price…

ROSEN, LEADING INVESTOR COUNSEL, Encourages AstraZeneca PLC Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – AZN

NEW YORK, Dec. 31, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm,…

AZN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that AstraZeneca PLC Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

NEW YORK, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally…

Oncology Pharmaceuticals Market Research 2024-2029, Profiles of Major Players - Bristol-Myers Squibb, Merck & Co, F. Hoffmann-La Roche, Johnson & Johnson, and AstraZeneca

This report seeks to deliver an in-depth analysis of the worldwide oncology pharmaceuticals (cancer medications) market. It includes a thorough…

Why IonQ Is the Best Quantum Computing Stock to Buy Right Now

Quantum computing represents the next frontier in computational power. Once developed, these systems could solve complex problems in drug development,…

AZN, Daiichi Withdraw EU Filing for Dato-DXd in Nonsquamous NSCLC

AstraZeneca and Daiichi Sankyo voluntarily withdraw regulatory filing for Dato-DXd in nonsquamous non-small cell lung cancer in the European Union.…

ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages AstraZeneca PLC Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – AZN

NEW YORK, Dec. 24, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm,…

AstraZeneca Aktie: Gute und schlechte Nachrichten um Weihnachten

Kulmbach (www.aktiencheck.de) - AstraZeneca-Aktienanalyse von "Der Aktionär": Michel Doepke vom Anlegermagazin "Der Aktionär" nimmt in einer aktuellen Aktienanalyse die Aktie von…

Achilles Therapeutics Announces Sale of Technology Assets to AstraZeneca

- Proprietary data and samples from TRACERx and Achilles’ Material Acquisition Platform (MAP) will be transferred to AstraZeneca under the…

Astrazeneca/Daiichi Sankyo ziehen EU-Zulassungsantrag für Lungenkrebsmittel zurück

DJ Astrazeneca/Daiichi Sankyo ziehen EU-Zulassungsantrag für Lungenkrebsmittel zurück Von Najat Kantouar Dow Jones--Die Pharmakonzerne AstraZeneca und Daiichi Sankyo ziehen ihren…

AstraZeneca pulls lung cancer drug application in EU

AstraZeneca PLC (LSE:AZN) has pulled a marketing authorisation application for its key lung cancer drug in the European Union. FTSE…

Dato-DXd NSQ NSCLC application withdrawn in EU

24 December 2024 Datopotamab deruxtecan application in the EU for patients with advanced nonsquamous non-small cell lung cancer voluntarily withdrawn AstraZeneca and Daiichi Sankyo…

AZN INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that AstraZeneca PLC Investors with Substantial Losses Have Opportunity to Lead the AstraZeneca Class Action Lawsuit

SAN DIEGO, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or…

dpa-AFX ProFeed